RVTY

Revvity Inc. (RVTY) | Rumor.io

Revvity

RVTY

Attention (50-day avg)0%

Attention rank (50-day avg)#1,759

Bullish sentiment (50-day avg)100%

Price to earnings ratio72.6

Market capitalization16.9B

Earnings per share2.08

Dividend yield (TTM)0.19%

Revenue (annual)2.9B

Net income (annual)241.2M

Social

What share of all stock conversation is about RVTY?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Sep 16

Revvity, Inc. (RVTY) is trending higher, jumping +8.5% in a broadly positive Healthcare session.
Revvity has been identified as a top gainer in the US stock market, with CNBC flagging it among the biggest midday movers on Wall Street.
Revvity is acquiring France-based Human Cell Design, adding human pancreatic beta-cell models for metabolic disease research, and has printed a new 52-week high.

Generated by AI

Sentiment

Of the messages about RVTY that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	100% 0	97.39% +33.02
Bearish	—	0% 0	0% 0	2.61% -33.02

Oct 30

Revvity, Inc. reported worse-than-expected Q3 results, missing EPS and revenue estimates.
The company lowered its FY23 guidance, reducing its adjusted EPS view and revenue forecast.
Revvity's stock price declined significantly, trading 395% and 504% above average volume, and closing down 10.2%, 15.21%, and 16.12% respectively.

Generated by AI

Topics

Of the messages about RVTY that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	66.67%	29.17%	14.19%
Announcements	—	33.33%	65%	48.58%
Analysts	—	0%	5.83%	10.68%
Earnings	—	0%	0%	25.88%
Controversies	—	0%	0%	0%
Macro	—	0%	0%	0.67%

Earnings· Feb 2

Revvity, Inc. (RVTY) reported Q4 revenue of $772M, up 6% year over year, with adjusted EPS of $1.70.
The company guided 2026 revenue to $2.96B to $2.99B and adjusted EPS of $5.35 to $5.45, with 2-3% organic growth.
Revvity's Q4 earnings beat initial expectations, with a 4% organic revenue growth in Q4, driven by the Diagnostics segment, but margins compressed and 2026 outlook is cautious.

Announcements· Feb 2

Revvity, Inc. reported Q4 revenue of $772M, beating estimates of $764M, with adjusted EPS of $1.70, exceeding expectations of $1.57.
The company's diagnostics segment achieved 7% organic growth in Q4, while its life sciences segment saw 0% organic growth.
Revvity provided guidance for FY26, projecting revenue of $2.96B to $2.99B and adjusted EPS of $5.35 to $5.45, representing 2-3% organic growth.

Generated by AI

Community

Of the messages about RVTY, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	1.06%	4.77%	26.45%
Newcomers	—	98.94%	95.23%	73.55%

Regulars· Feb 2

Revvity, Inc. reported Q4 revenue of $772M, a 6% year-over-year increase, with adjusted EPS of $1.70.
The company provided 2026 revenue guidance of $2.96B to $2.99B and adjusted EPS of $5.35 to $5.45, exceeding estimates.
Despite a cautious outlook, Revvity's strong Q4 results, improving Life Sciences trends, and aggressive buybacks suggest a more focused growth story.

Newcomers· Feb 2

Revvity, Inc. (RVTY) reported Q4 earnings of $1.70 per share, beating the FactSet consensus of $1.57.
The company guided FY26 EPS above consensus, with revenue guidance also above expectations, ranging from $2.96B to $2.99B.
RVTY's strong guidance and revenue growth have sparked speculation about a potential breakout, with some analysts suggesting it may be a strategic options play for long-term investors.

Generated by AI

Revvity has been on fire lately. In the past six months alone, the company’s stock price has rocketed 78%, reaching $150.93 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

18h agoYahoo Finance

Here's Why You Should Retain Revvity Stock in Your Portfolio for Now

RVTY's diagnostics growth, AI-driven demand and life sciences expansion support its outlook, though China and margin pressures pose near-term challenges.

22h agoYahoo Finance

Revvity options flow shows 156:1 call-to-put ratio ahead of Nov. 2026 expiry

4d agoInvesting.com

RVTY Launches New Kit in Europe for Newborn Type 1 Diabetes Detection

Revvity launches a CE-IVDR-certified automated T1D screening kit for children, expanding its GSP platform from newborn screening into early childhood.

4d agoYahoo Finance Singapore

Full Transcript: Revvity Q2 2026 Earnings Call - Revvity (NYSE:RVTY)

Revvity (NYSE:RVTY) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by Benzinga APIs. For

5d agobenzinga.com

Also Discussed

Investors talking about RVTY also mention

#	Name	Attention
1	IQVIA Holdings Inc.IQV	0%0
2	PACCAR Inc.PCAR	0%0
3	F5, Inc.FFIV	0.01%+0.01
4	The J.M. Smucker CompanySJM	0%new
5	Becton, Dickinson and CompanyBDX	0%0
6	Pacific Biosciences of California, Inc. Common StockPACB	0%0
7	Qiagen N.V.QGEN	0%+0
8	Fulgent Genetics, Inc.FLGT	0%0
9	Bruker CorpBRKR	0%+0
10	Aptiv PLCAPTV	0%new

Revvity Inc.

Healthcare
Diagnostics & Research

Revvity Inc. is a health science tools and diagnostics company that provides end-to-end solutions for research, development, testing, and clinical use. The company operates through two main segments: Life Sciences and Diagnostics, serving customers across pharmaceutical and biotechnology companies, diagnostic laboratories, academic institutions, and government organizations. Its portfolio includes reagents, consumables, assays, instruments, software, and specialized services that support workflows from discovery through diagnosis. Revvity focuses on areas such as translational multi-omics, biomarker identification, imaging, screening, detection, informatics, reproductive health, immunodiagnostics, and genomic testing. It also supports applications in rare disease testing, newborn screening, hereditary cancer, and broader clinical laboratory services. Based in Waltham, Massachusetts, Revvity plays an important role in the healthcare and life sciences ecosystem by helping researchers, clinicians, and laboratories generate and analyze data across a wide range of scientific and diagnostic applications.

Website

Location

77 4th Avenue

Waltham, MA, 02451

United States

Social

What share of all stock conversation is about RVTY?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Sep 16

Revvity, Inc. (RVTY) is trending higher, jumping +8.5% in a broadly positive Healthcare session.
Revvity has been identified as a top gainer in the US stock market, with CNBC flagging it among the biggest midday movers on Wall Street.
Revvity is acquiring France-based Human Cell Design, adding human pancreatic beta-cell models for metabolic disease research, and has printed a new 52-week high.

Generated by AI

Sentiment

Of the messages about RVTY that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	100% 0	97.39% +33.02
Bearish	—	0% 0	0% 0	2.61% -33.02

Oct 30

Revvity, Inc. reported worse-than-expected Q3 results, missing EPS and revenue estimates.
The company lowered its FY23 guidance, reducing its adjusted EPS view and revenue forecast.
Revvity's stock price declined significantly, trading 395% and 504% above average volume, and closing down 10.2%, 15.21%, and 16.12% respectively.

Generated by AI

Topics

Of the messages about RVTY that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	66.67%	29.17%	14.19%
Announcements	—	33.33%	65%	48.58%
Analysts	—	0%	5.83%	10.68%
Earnings	—	0%	0%	25.88%
Controversies	—	0%	0%	0%
Macro	—	0%	0%	0.67%

Earnings· Feb 2

Revvity, Inc. (RVTY) reported Q4 revenue of $772M, up 6% year over year, with adjusted EPS of $1.70.
The company guided 2026 revenue to $2.96B to $2.99B and adjusted EPS of $5.35 to $5.45, with 2-3% organic growth.
Revvity's Q4 earnings beat initial expectations, with a 4% organic revenue growth in Q4, driven by the Diagnostics segment, but margins compressed and 2026 outlook is cautious.

Announcements· Feb 2

Revvity, Inc. reported Q4 revenue of $772M, beating estimates of $764M, with adjusted EPS of $1.70, exceeding expectations of $1.57.
The company's diagnostics segment achieved 7% organic growth in Q4, while its life sciences segment saw 0% organic growth.
Revvity provided guidance for FY26, projecting revenue of $2.96B to $2.99B and adjusted EPS of $5.35 to $5.45, representing 2-3% organic growth.

Generated by AI

Community

Of the messages about RVTY, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	1.06%	4.77%	26.45%
Newcomers	—	98.94%	95.23%	73.55%

Regulars· Feb 2

Revvity, Inc. reported Q4 revenue of $772M, a 6% year-over-year increase, with adjusted EPS of $1.70.
The company provided 2026 revenue guidance of $2.96B to $2.99B and adjusted EPS of $5.35 to $5.45, exceeding estimates.
Despite a cautious outlook, Revvity's strong Q4 results, improving Life Sciences trends, and aggressive buybacks suggest a more focused growth story.

Newcomers· Feb 2

Revvity, Inc. (RVTY) reported Q4 earnings of $1.70 per share, beating the FactSet consensus of $1.57.
The company guided FY26 EPS above consensus, with revenue guidance also above expectations, ranging from $2.96B to $2.99B.
RVTY's strong guidance and revenue growth have sparked speculation about a potential breakout, with some analysts suggesting it may be a strategic options play for long-term investors.

Generated by AI

Revvity

Social

Sep 16

Sentiment

Oct 30

Topics

Earnings· Feb 2

Announcements· Feb 2

Community

Regulars· Feb 2

Newcomers· Feb 2

News

Revvity Inc. stock outperforms competitors on strong trading day

Revvity (RVTY): Buy, Sell, or Hold Post Q2 Earnings?

Here's Why You Should Retain Revvity Stock in Your Portfolio for Now

Revvity options flow shows 156:1 call-to-put ratio ahead of Nov. 2026 expiry

RVTY Launches New Kit in Europe for Newborn Type 1 Diabetes Detection

Full Transcript: Revvity Q2 2026 Earnings Call - Revvity (NYSE:RVTY)

Also Discussed

Revvity Inc.

Company Information

Location

News

Revvity Inc. stock outperforms competitors on strong trading day

Revvity (RVTY): Buy, Sell, or Hold Post Q2 Earnings?

Here's Why You Should Retain Revvity Stock in Your Portfolio for Now

Revvity options flow shows 156:1 call-to-put ratio ahead of Nov. 2026 expiry

RVTY Launches New Kit in Europe for Newborn Type 1 Diabetes Detection

Full Transcript: Revvity Q2 2026 Earnings Call - Revvity (NYSE:RVTY)

Also Discussed

Social

Sep 16

Sentiment

Oct 30

Topics

Earnings· Feb 2

Announcements· Feb 2

Community

Regulars· Feb 2

Newcomers· Feb 2